As regards the pregnant women, it should be noted that the data relating to the use of Nuvaxovid are limited but that “animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo-fetal development, parturition or postnatal development”. “The administration of Nuvaxovid in pregnancy should only be considered when the potential benefits outweigh the potential risks to the mother and fetus,” explains the circular. Furthermore, “Nuvaxovid is not expected to cause effects on newborns / infants”
